Document is current
Any future updates will be listed below
-
Authors
Marcucci, Maura https://orcid.org/0000-0002-8468-7991
Duceppe, Emmanuelle
Le Manach, Yannick
Kearon, Clive
Eikelboom, John W.
Pohl, Kayla
Vincent, Jessica
Darvish-Kazem, Saeed
Srinathan, Sadeesh K.
Neary, John D. D.
Parlow, Joel L.
Kurz, Andrea
Gross, Peter L.
Mrkobrada, Marko
Balasubramanian, Kumar
Sessler, Daniel I.
Devereaux, P. J.
-
Funding
Funding for this research was provided by:
Pfizer Canada
Hamilton Academic Health Sciences Organization (Innovation Grant)
Hamilton Health Sciences (New Investigator Fund)
- License Information
-
More Information
Article History
Received: 11 September 2019
Accepted: 6 July 2020
First Online: 21 July 2020
Ethics approval and consent to participate
: Ethics approval was acquired prior to the commencement of the study from the Hamilton Health Science Research Ethics Board. All patients provided their consent to be enrolled in the study.
: Not applicable.
: Clive Kearon has received grants from Bayer and personal fees from Bayer and Bristol-Myers Squibb. John W. Eikelboom has received honoraria and grant support from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, Daiichi Sankyo, Glaxo Smith Kline, Janssen, Sanofi-Aventis, and Eli Lilly and a personal award from the Heart and Stroke Foundation. Saeed Darvish-Kazem has received speaking honorarium from Novartis, Servier, and Bayer. Peter L. Gross has received speaker, consulting honoraria, and/or research grant support from Bayer, Pfizer, and Bristol-Myers Squibb. P.J. Devereaux has received grants from Abbott Diagnostics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Covidien, Stryker, and Roche Diagnostics and has participated in an advisory board meeting for GlaxoSmithKline and an expert panel meeting for AstraZeneca. No other competing interests were declared.
